Skip to main
CING

Cingulate (CING) Stock Forecast & Price Target

Cingulate (CING) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cingulate Inc is positioned favorably in the ADHD medication market, which has seen consistent growth of approximately 8% annually, culminating in sales of around $18 billion in 2020. The company is focusing on the development of its proprietary ADHD medications, CTx-1301 and CTx-1302, with regulatory approval anticipated in mid-2026, potentially serving as a strong catalyst for stock performance. Furthermore, the current valuation of Cingulate stock appears attractive when assessed through a net present value analysis, indicating significant upside potential relative to the existing share price despite inherent risks.

Bears say

Cingulate Inc reported a net loss of $7.3 million, equating to an earnings per share (EPS) of $(1.35), which significantly exceeded both the company's estimates and consensus expectations for the quarter. The company also recorded a previous net loss of $6.5 million with an EPS of $(0.93), which again fell short of its and the market's projections. Key risks affecting the outlook include liquidity challenges, the potential inability of product candidates to prove safety and efficacy, regulatory approval hurdles, commercialization difficulties, reimbursement issues, and broader competitive and economic pressures impacting investor sentiment towards biotech stocks.

Cingulate (CING) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cingulate and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cingulate (CING) Forecast

Analysts have given Cingulate (CING) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Cingulate (CING) has a Strong Buy consensus rating as of Apr 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $34.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $34.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cingulate (CING)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.